[CAS NO. 1425944-22-4] CYD-2-11

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1425944-22-4]

Catalog

HY-120275

Brand

MCE

CAS

1425944-22-4

DESCRIPTION [1425944-22-4]

Overview

MDL	-
Molecular Weight	358.39
Molecular Formula	C22H18N2O3
SMILES	NCCOC1=CC=CC=C1/C=C2C3=C(C=CC([N+]([O-])=O)=C3)C4=C/2C=CC=C4

For research use only. We do not sell to patients.

Summary

CYD-2-11 is a selective Bax agonist with a K _i value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC ₅₀ values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer ^[1] ^[2] .

In Vitro

CYD-2-11 (0-100 μM; 48 h) shows anti-proliferation effects to breast cancer cells ^[1] .
CYD-2-11 (5 μM; 48 h) selectively binds to Bax protein and induces apoptosis in NSCLC and SCLC cell lines ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[1]

Cell Line:	T47D, MCF-7, MDA-MB-231, MDA-MB-468 and MCF-10A cell lines
Concentration:	0.01, 0.1, 1, 5, 10 and 100 µM
Incubation Time:	48 hours
Result:	Inhibited cell proliferation of T47D, MCF-7, MDA-MB-231, MDA-MB-468 and MCF-10A cells with IC ₅₀ values of 4.37, 9.47, 3.81, 3.22 and 8.73 μM, respectively.

Apoptosis Analysis ^[2]

Cell Line:	SCLC and NSCLC cell lines
Concentration:	5 µM
Incubation Time:	48 hours
Result:	Induced cell apoptosis in both SCLC and NSCLC cells with a higher effect than SMBA1.

In Vivo

CYD-2-11 (20 mg/kg; i.p.; once daily for 7 days) inhibits tumor growth ^[1] .
CYD-2-11 (40 mg/kg; i.p.; once daily for 14 days) represses lung cancer growth and overcomes rapalog resistance with the combination of RAD001 (1 mg/kg) in murine lung cancer models ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice with MDA-MB-231 tumor xenografts ^[1]
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; 20 mg/kg; once daily for 7 days
Result:	Exhibited a 57% inhibition rate of MDA-MB-231 tumor growth in vivo.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.